26 Feb Pressure mounts on Bayer CEO to fix legal problems as chairman quits

Bayer | St. Louis Post-Dispatch | Ludwig Burger and Patricia Weiss | Feb 26, 2020 – Updated at 12:30 p.m.

Bayer Chairman Werner Wenning strongly supported Baumann’s pursuit of Monsanto

FRANKFURT, Germany — The departure of Bayer Chairman Werner Wenning will turn up the heat on CEO Werner Baumann to resolve the company’s continuing legal problems, two of the firm’s biggest German shareholders said on Wednesday.

Bayer’s shares have plunged about a quarter in value since August 2018, when the company lost a U.S. lawsuit claiming that weedkiller Roundup — acquired via its $63 billion takeover of Creve Coeur-based Monsanto earlier in the year — causes cancer.

Wenning, who strongly supported Baumann’s pursuit of Monsanto, said earlier on Wednesday he would step down at the company’s annual shareholder meeting in April.

He will be replaced by Norbert Winkeljohann, the former head of Europe at audit and consulting firm PricewaterhouseCoopers, who joined Bayer’s non-executive supervisory board in 2018 and did not play a role in the Monsanto deal.

“What speaks in favor of Winkeljohann is the fact that he can look at the Monsanto issue with fresh eyes,” said Ingo Speich, a fund manager at Deka Investment.

“That can be a challenge for Baumann, particularly in the difficult phase that the company is in,” he said, adding he did not think Baumann was in immediate danger of losing his job.

Janne Werning, in charge of environmental, social and governance issues at Union Investment, said Wenning’s departure came at the right time.

“Mr. Wenning was closely associated with the current difficult situation. It’s now essential that Bayer’s further strategic positioning is subject to independent oversight,” he told Reuters in a written comment.

Bayer’s top management faced an unprecedented show of shareholder disapproval

Both Speich and Werning were disappointed, however, that Winkeljohann has no expertise in running international health care or agriculture businesses.

That drawback is compounded by the fact another board nominee, the former finance chief of travel group TUI, Horst Baier, also brings no specific industry experience, said Union’s Werning.

Deka and Union are among Bayer’s top 20 investors, according to Refinitiv data. They declined to give the size of their holdings.

With the number of Roundup lawsuits rising, Bayer’s top management faced an unprecedented show of shareholder disapproval at last April’s annual general meeting.

The company is now in talks to settle the claims, with some analysts saying that could cost it up to $12 billion.

“As Mr Baumann has lost one of his most important supporters, his future in Bayer might be … uncertain and linked to the share price development of Bayer after the settlement announcement,” said Baader Helvea analyst Markus Mayer in a research note.

“Our earlier story, posted at 6:04 a.m.

FRANKFURT — Bayer Chairman Werner Wenning, one of the architects of a $63 billion takeover deal that has left the German crop protection company fighting costly lawsuits, will step down in April, it said on Wednesday.

Bayer shares have plunged about a quarter in value since August 2018, when the company lost the first U.S. lawsuit claiming weedkiller Roundup — acquired via the takeover of Monsanto — causes cancer.

“We have made and continue to make progress in handling the legal issues in the U.S. That’s why now is a good time to hand over to my successor,” the 73-year-old Wenning said in a statement.

Norbert Winkeljohann, who was head of auditing firm PricewaterhouseCoopers Europe SE until June 2018 and has been a member of Bayer’s supervisory board since 2018, will succeed Wenning after the annual shareholders’ meeting on April 28, the company added.

Wenning, whose term as chairman of Bayer’s non-executive supervisory board would have expired in 2022, said he had originally intended to step down last year after reaching the board’s recommended age limit of 72, but was asked to stay on.

Bayer last year started negotiations with plaintiffs’ lawyers to settle more U.S. lawsuits involving Roundup.

In October 2019, the number of plaintiffs more than doubled to 42,700 within just three months, and analysts have predicted it may cost they company up to $12 billion to lay the claims to rest.

In August 2018, a California state court jury awarded almost $300 million in damages to a groundskeeper in the initial Roundup lawsuit, though that was later reduced to $78 million.

In two subsequent cases other juries also found the company liable. Bayer is appealing all three verdicts.

Major shareholders have criticized Bayer for its handling of the issue and for underestimating the risks when it bought Monsanto, resulting in an unprecedented show of disapproval towards top management at last year’s annual general meeting.

Bayer, which is scheduled to release fourth-quarter results on Thursday, has defended a deal that brought together companies commanding more than a quarter of the world market for seeds and pesticides.

Wenning, a Bayer veteran of more than 50 years, became CEO in 2002, taking control of a company plunged into crisis by the 2001 market withdrawal of cholesterol drug Baycol, or Lipobay, which had been linked to deadly side effects.

As CEO, he clinched major takeovers including that of Roche’s non-prescription drugs business for 2.4 billion euros ($3.2 billion) and of German health care rival Schering for 17 billion euros.

After an eight-year stint, he handed the CEO role to company outsider Marijn Dekkers in 2010 and became chairman two years later. Wenning’s protégé Werner Baumann succeeded Dekkers as CEO in 2016 after serving as finance chief and head of strategy.

Within weeks of taking the helm, Baumann broke cover on Bayer’s interest in Monsanto, enjoying unwavering support from Wenning throughout the tortuous negotiations and also as Roundup lawsuits piled in later.

Pesticide market regulators across the globe, including the U.S. Environmental Protection Agency (EPA) and the European Food Safety Authority have concluded that Roundup is not likely carcinogenic to humans.

The World Health Organization’s International Agency for Research on Cancer (IARC), however, stated in 2015 that glyphosate — which is used in Roundup — probably causes cancer.”

FREE Consultation |  314-833-4827

Dicamba Damage Lawyers at Peiffer Wolf Carr & Kane are fighting on behalf of farmers and landowners to seek maximum compensation for the damages suffered due to Dicamba Damage. If you suspect that your crops or plants have been damaged by dicamba, contact Peiffer Wolf Carr & Kane by filling out a Contact Form or by calling 314-833-4827 for a FREE Consultation.